|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0035820,
umls-concept:C0086418,
umls-concept:C0185117,
umls-concept:C0242643,
umls-concept:C0334227,
umls-concept:C0376622,
umls-concept:C0851285,
umls-concept:C1101610,
umls-concept:C1704939,
umls-concept:C1823242,
umls-concept:C2911684
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-8-18
|
|
pubmed:abstractText |
MicroRNAs are short non-coding RNA molecules able to affect stability and/or translation of mRNA, thereby regulating the expression of genes involved in many biological processes. We report here that microRNAs miR-27a and miR-451 are involved in activating the expression of P-glycoprotein, the MDR1 gene product that confers cancer cell resistance to a broad range of chemotherapeutics. We showed that expressions of miR-27a and miR-451 were up-regulated in multidrug resistant (MDR) cancer cell lines A2780DX5 and KB-V1, as compared with their parental lines A2780 and KB-3-1. Treatment of A2780DX5 cells with the antagomirs of miR-27a or miR-451 decreased the expression of P-glycoprotein and MDR1 mRNA. In contrast, the mimics of miR-27a and miR-451 increased MDR1 expression in the parental cells A2780. The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451. Our results demonstrate for the first time the roles of microRNAs in the regulation of drug resistance mediated by MDR1/P-glycoprotein, and suggest the potential for targeting miR-27a and miR-451 as a therapeutic strategy for modulating MDR in cancer cells.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-10589744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-10644769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-11562428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-12670898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-14530494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-14744438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-15210942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-15498565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-15979303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-16054595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-16405967,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-16439997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-17020948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-1703776,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-17072344,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-17350266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-17662696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-17686970,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-18199536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-1967174,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-2243668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-8096875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-8454045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18619946-8466853
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1873-2968
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
582-8
|
|
pubmed:dateRevised |
2011-1-10
|
|
pubmed:meshHeading |
pubmed-meshheading:18619946-Base Sequence,
pubmed-meshheading:18619946-Blotting, Western,
pubmed-meshheading:18619946-Cell Line, Tumor,
pubmed-meshheading:18619946-DNA Primers,
pubmed-meshheading:18619946-Doxorubicin,
pubmed-meshheading:18619946-Drug Resistance, Neoplasm,
pubmed-meshheading:18619946-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18619946-Humans,
pubmed-meshheading:18619946-MicroRNAs,
pubmed-meshheading:18619946-Neoplasms,
pubmed-meshheading:18619946-P-Glycoprotein,
pubmed-meshheading:18619946-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18619946-Rhodamine 123
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells.
|
|
pubmed:affiliation |
Department of Pharmacology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, NJ 08903, United States.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
